Investigational drug · Phase 3
VLA15
Also called: PF-07307405
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lyme Disease, Lyme Borreliosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
8
Any phase or sponsor naming "VLA15"
First trial start
2022
Aug 4, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VLA15", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lyme Disease
- Lyme Borreliosis
Largest trials
Live from ClinicalTrials.gov: studies naming "VLA15" as an intervention, largest first.
- An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05477524 · 12,546 participants · Start Aug 4, 2022 · Primary completion Jan 7, 2026
Drug: VLA15 · For: Lyme Disease
Sites: Essex, Connecticut; Ledyard Center, Connecticut; New London, Connecticut · 129 sites in all
- Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy ChildrenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05634811 · 3,547 participants · Start Dec 12, 2022 · Primary completion Jul 21, 2025
Drug: VLA15 · For: Lyme Disease
Sites: Birmingham, Alabama; Guntersville, Alabama; Bellflower, California · 65 sites in all
- A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07500506 · 1,712 participants (planned) · Start Apr 8, 2026 · Primary completion Dec 4, 2026
Drug: VLA15; Placebo · For: Lyme Disease
Sites: Bangor, Maine; Worcester, Massachusetts; Flemington, New Jersey · 22 sites in all
- Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study PopulationPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04801420 · 625 participants · Start Mar 8, 2021 · Primary completion Mar 25, 2022
Drug: VLA15; Placebo · For: Lyme Borreliosis
Sites: Bridgeport, Connecticut; Stamford, Connecticut; Waterbury, Connecticut · 19 sites in all
- Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03769194 · 572 participants · Start Dec 17, 2018 · Primary completion Dec 18, 2019
Drug: VLA15; Placebo · For: Lyme Borreliosis
Sites: Milford, Connecticut; Stamford, Connecticut; Binghamton, New York · 9 sites in all
- Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme BorreliosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03970733 · 246 participants · Start Jul 1, 2019 · Primary completion Apr 7, 2020
Drug: VLA15; Placebo · For: Lyme Borreliosis
Sites: Milford, Connecticut; Stamford, Connecticut; Binghamton, New York · 5 sites in all
- A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy AdultsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07226882 · 207 participants · Start Nov 19, 2025 · Primary completion Jan 27, 2028
Drug: VLA15; Placebo · For: Lyme Borreliosis
Sites: Warren Township, New Jersey; Cortland, New York; Horseheads, New York · 6 sites in all
- Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme BorreliosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03010228 · 179 participants · Start Jan 31, 2017 · Primary completion Sep 28, 2017
Drug: VLA15 with Alum; VLA15 without Alum · For: Lyme Borreliosis, Nervous System
Sites: La Mesa, California; Lincoln, Nebraska; Ghent, Belgium · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary.
Wagner L, Messier M, Stark JH, et al. · Expert Rev Vaccines 2026
- A human Lyme disease vaccine: two steps forward on the path to prevention.
Simon R, Lamberth E, Stark JH, et al. · Expert Rev Vaccines 2026
- Retraction: Exploring the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk population: a systematic review and meta-analysis of randomized controlled trials.
· Ther Adv Vaccines Immunother 2026
- Lessons Unlearned: The Barriers to Lyme Borreliosis Vaccination and the Risk of Repeating History.
Nagra D, Biddle K, Bechman K, et al. · Vaccines (Basel) 2026
- A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
Wagner L, Kadlecek V, Skaroupkova J, et al. · Nat Commun 2026
- Epidemiology, diagnosis and emerging therapies for Lyme disease of the Northern Hemisphere.
Priya S, Sridhar SB, Shareef J, et al. · Int J Emerg Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.